CARIBOU BIOSCIENCES INC (CRBU) Fundamental Analysis & Valuation

NASDAQ:CRBU • US1420381089

1.82 USD
+0.11 (+6.43%)
At close: Mar 6, 2026
1.82 USD
0 (0%)
After Hours: 3/6/2026, 8:09:43 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This CRBU fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Taking everything into account, CRBU scores 3 out of 10 in our fundamental rating. CRBU was compared to 519 industry peers in the Biotechnology industry. While CRBU seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, CRBU is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. CRBU Profitability Analysis

1.1 Basic Checks

  • CRBU had negative earnings in the past year.
  • In the past year CRBU has reported a negative cash flow from operations.
  • In the past 5 years CRBU always reported negative net income.
  • CRBU had a negative operating cash flow in each of the past 5 years.
CRBU Yearly Net Income VS EBIT VS OCF VS FCFCRBU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

  • The Return On Assets of CRBU (-80.58%) is worse than 67.88% of its industry peers.
  • Looking at the Return On Equity, with a value of -110.77%, CRBU is in line with its industry, outperforming 42.12% of the companies in the same industry.
Industry RankSector Rank
ROA -80.58%
ROE -110.77%
ROIC N/A
ROA(3y)-32.6%
ROA(5y)-41.65%
ROE(3y)-39.9%
ROE(5y)-65.73%
ROIC(3y)N/A
ROIC(5y)N/A
CRBU Yearly ROA, ROE, ROICCRBU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CRBU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRBU Yearly Profit, Operating, Gross MarginsCRBU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. CRBU Health Analysis

2.1 Basic Checks

  • CRBU does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CRBU has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for CRBU has been increased compared to 5 years ago.
  • There is no outstanding debt for CRBU. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRBU Yearly Shares OutstandingCRBU Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CRBU Yearly Total Debt VS Total AssetsCRBU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • CRBU has an Altman-Z score of -3.94. This is a bad value and indicates that CRBU is not financially healthy and even has some risk of bankruptcy.
  • CRBU has a Altman-Z score of -3.94. This is comparable to the rest of the industry: CRBU outperforms 42.69% of its industry peers.
  • CRBU has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.94
ROIC/WACCN/A
WACC8.79%
CRBU Yearly LT Debt VS Equity VS FCFCRBU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

  • CRBU has a Current Ratio of 5.54. This indicates that CRBU is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 5.54, CRBU perfoms like the industry average, outperforming 59.23% of the companies in the same industry.
  • A Quick Ratio of 5.54 indicates that CRBU has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 5.54, CRBU is doing good in the industry, outperforming 60.58% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.54
Quick Ratio 5.54
CRBU Yearly Current Assets VS Current LiabilitesCRBU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. CRBU Growth Analysis

3.1 Past

  • CRBU shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.03%.
  • CRBU shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -19.00%.
  • CRBU shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.54% yearly.
EPS 1Y (TTM)-3.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.05%
Revenue 1Y (TTM)-19%
Revenue growth 3Y1.35%
Revenue growth 5Y11.54%
Sales Q2Q%8.6%

3.2 Future

  • CRBU is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.70% yearly.
  • The Revenue is expected to grow by 61.30% on average over the next years. This is a very strong growth
EPS Next Y0.58%
EPS Next 2Y8.14%
EPS Next 3Y5.91%
EPS Next 5Y8.7%
Revenue Next Year-5.46%
Revenue Next 2Y-0.19%
Revenue Next 3Y3.25%
Revenue Next 5Y61.3%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CRBU Yearly Revenue VS EstimatesCRBU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2B 4B 6B 8B
CRBU Yearly EPS VS EstimatesCRBU Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. CRBU Valuation Analysis

4.1 Price/Earnings Ratio

  • CRBU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year CRBU is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRBU Price Earnings VS Forward Price EarningsCRBU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRBU Per share dataCRBU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.14%
EPS Next 3Y5.91%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CRBU Dividend Analysis

5.1 Amount

  • CRBU does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CRBU Fundamentals: All Metrics, Ratios and Statistics

CARIBOU BIOSCIENCES INC

NASDAQ:CRBU (3/6/2026, 8:09:43 PM)

After market: 1.82 0 (0%)

1.82

+0.11 (+6.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-02
Earnings (Next)05-04
Inst Owners38.23%
Inst Owner Change-4.44%
Ins Owners4.32%
Ins Owner Change19.43%
Market Cap170.12M
Revenue(TTM)9.29M
Net Income(TTM)-157.13M
Analysts85.33
Price Target11.33 (522.53%)
Short Float %9.25%
Short Ratio6.27
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-13.34%
Min EPS beat(2)-45.06%
Max EPS beat(2)18.38%
EPS beat(4)3
Avg EPS beat(4)-3.23%
Min EPS beat(4)-45.06%
Max EPS beat(4)18.38%
EPS beat(8)5
Avg EPS beat(8)-0.45%
EPS beat(12)9
Avg EPS beat(12)7.25%
EPS beat(16)12
Avg EPS beat(16)6.44%
Revenue beat(2)1
Avg Revenue beat(2)-8.7%
Min Revenue beat(2)-23.49%
Max Revenue beat(2)6.09%
Revenue beat(4)2
Avg Revenue beat(4)2.78%
Min Revenue beat(4)-23.49%
Max Revenue beat(4)31.82%
Revenue beat(8)3
Avg Revenue beat(8)-6.92%
Revenue beat(12)7
Avg Revenue beat(12)52.34%
Revenue beat(16)8
Avg Revenue beat(16)37.54%
PT rev (1m)2.17%
PT rev (3m)-0.12%
EPS NQ rev (1m)3.56%
EPS NQ rev (3m)9.96%
EPS NY rev (1m)0%
EPS NY rev (3m)5.49%
Revenue NQ rev (1m)-3.34%
Revenue NQ rev (3m)1.7%
Revenue NY rev (1m)-1.2%
Revenue NY rev (3m)-8.37%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 18.3
P/FCF N/A
P/OCF N/A
P/B 1.2
P/tB 1.2
EV/EBITDA N/A
EPS(TTM)-1.7
EYN/A
EPS(NY)-1.37
Fwd EYN/A
FCF(TTM)-1.37
FCFYN/A
OCF(TTM)-1.34
OCFYN/A
SpS0.1
BVpS1.52
TBVpS1.52
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -80.58%
ROE -110.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32.6%
ROA(5y)-41.65%
ROE(3y)-39.9%
ROE(5y)-65.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 50.47%
Cap/Sales 22.52%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.54
Quick Ratio 5.54
Altman-Z -3.94
F-Score3
WACC8.79%
ROIC/WACCN/A
Cap/Depr(3y)283.95%
Cap/Depr(5y)220.75%
Cap/Sales(3y)43.03%
Cap/Sales(5y)30.75%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.05%
EPS Next Y0.58%
EPS Next 2Y8.14%
EPS Next 3Y5.91%
EPS Next 5Y8.7%
Revenue 1Y (TTM)-19%
Revenue growth 3Y1.35%
Revenue growth 5Y11.54%
Sales Q2Q%8.6%
Revenue Next Year-5.46%
Revenue Next 2Y-0.19%
Revenue Next 3Y3.25%
Revenue Next 5Y61.3%
EBIT growth 1Y11.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.39%
EBIT Next 3Y2.42%
EBIT Next 5YN/A
FCF growth 1Y-18.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-29.58%
OCF growth 3YN/A
OCF growth 5YN/A

CARIBOU BIOSCIENCES INC / CRBU FAQ

Can you provide the ChartMill fundamental rating for CARIBOU BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 3 / 10 to CRBU.


What is the valuation status for CRBU stock?

ChartMill assigns a valuation rating of 0 / 10 to CARIBOU BIOSCIENCES INC (CRBU). This can be considered as Overvalued.


Can you provide the profitability details for CARIBOU BIOSCIENCES INC?

CARIBOU BIOSCIENCES INC (CRBU) has a profitability rating of 0 / 10.


What is the earnings growth outlook for CARIBOU BIOSCIENCES INC?

The Earnings per Share (EPS) of CARIBOU BIOSCIENCES INC (CRBU) is expected to grow by 0.58% in the next year.